Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05798117
Other study ID # CYTB323G12101
Secondary ID 2022-001796-14
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date February 28, 2023
Est. completion date October 9, 2026

Study information

Verified date May 2024
Source Novartis
Contact Novartis Pharmaceuticals
Phone 1-888-669-6682
Email novartis.email@novartis.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date October 9, 2026
Est. primary completion date October 9, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Signed informed consent - Adequate renal, hepatic, cardiac, hematological and pulmonary function - Men and women with SLE, aged =18 years and =65 years at screening, fulfilling the 2019 European League Against Rheumatism EULAR/ACR classification criteria for SLE. - Patient must be positive for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) at a titer of =1:80, or anti dsDNA (above the ULN); or anti-Sm (above the ULN) - Active (severe) disease as defined by SLEDAI-2K = 8 (not including the SLEDAI-2K domains of lupus headache, cerebrovascular accident, organic brain syndrome) and at least one of the following significant SLE related organ involvements: - Renal - At least moderate or severe peri/myocarditis - At least moderate or severe pleuritis or other lung involvement - Vasculitis - Failure to respond to two or more standard immunosuppressive therapies (including one of mycophenolate or cyclophosphamide), unless contraindicated or having experienced documented adverse events or intolerance related to such immunosuppressive drugs not allowing their further use, in combination with glucocorticoids and failure to respond to at least one biological agent (unless contraindicated, the patient deemed ineligible by the Investigator or not available in a country). Exclusion Criteria: - Clinically significant active, opportunistic, chronic or recurrent infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA, such as COVID-19 etc.) one month prior to or during screening. Patients who have had at least one severe infection that required prolonged hospitalization in the intensive care setting within 5 years prior to screening and/or at least one severe infection that required prolonged hospitalization within one year prior to screening. - Uncontrolled diabetes mellitus, lung diseases or any other illness that are not related to SLE that in the opinion of the Investigator would jeopardize the ability of the patient to tolerate lymphodepletion and CD19 CAR-T cell therapy - Prior history of malignancy except for localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis - Any patients requiring medications prohibited by the protocol - Any psychiatric condition or disability making compliance with treatment or informed consent impossible - Prior treatment with anti-CD19 therapy, adoptive T cell therapy or any prior gene therapy product (e.g. CAR-T cell therapy) - History of bone marrow/hematopoietic stem cell or solid organ transplantation - Female participants who are pregnant or breastfeeding, or intending to conceive during the course of the study - Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a highly effective method of contraception starting from the time of enrollment to at least 12 months after the YTB323 infusion and until CAR-T cells are no longer present by qPCR on two consecutive tests - Sexually active males unwilling to use a condom during intercourse from the time enrollment for at least 12 months after the YTB323 infusion and until CAR-T cells are no longer present by qPCR on two consecutive tests - Any acute, severe lupus related flare during screening that needs immediate treatment and/or makes the immunosuppressive washout impossible; thus, makes the patient ineligible for CD19 CAR-T therapy as judged by the Investigator, such as acute central nervous system (CNS) lupus (e.g. psychosis, epilepsy) or catastrophic antiphospholipid syndrome - Significant, likely irreversible organ damage related to SLE, e.g. end stage renal disease, that in the opinion of the Investigator renders CD19 CAR-T cell therapy would be unlikely to benefit the patient - B cell aplasia

Study Design


Intervention

Drug:
YTB323
Single infusion of YTB323

Locations

Country Name City State
Australia Novartis Investigative Site Clayton Victoria
France Novartis Investigative Site Lille
France Novartis Investigative Site Paris 13
France Novartis Investigative Site Pessac Cedex
France Novartis Investigative Site Strasbourg
Germany Novartis Investigative Site Freiburg
Germany Novartis Investigative Site Mainz
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site Madrid
Switzerland Novartis Investigative Site Bern
Switzerland Novartis Investigative Site Lausanne
United States Division of Rheumatology Immunology Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Australia,  France,  Germany,  Spain,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with AEs and SAEs Long term safety follow up Day 1 to 2 years
Secondary CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Maximum observed blood concentration Cmax) Blood samples will be collected to assess cellular kinetics. Pre-dose, up to 2 years
Secondary CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Area under plasma concentration -time AUC) Blood samples will be collected to assess cellular kinetics. Pre-dose, up to 2 years
Secondary CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach maximum concentration Tmax) Blood samples will be collected to assess cellular kinetics. Pre-dose, up to 2 years
Secondary CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Terminal elimination half-life T1/2) Blood samples will be collected to assess cellular kinetics. Pre-dose, up to 2 years
Secondary CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Last measurable concentration Clast) Blood samples will be collected to assess cellular kinetics. Pre-dose, up to 2 years
Secondary CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach last measurable concentration Tlast) Blood samples will be collected to assess cellular kinetics. Pre-dose, up to 2 years
Secondary Number of patients with anti-drug antibodies Blood samples will be collected to measure anti-drug antibodies against YTB323. Pre-dose, up to 2 years
Secondary Level of T cell activation by YTB323 Blood samples will be collected to measure the level of T cell activation by YTB323. Pre-dose, up to 2 years
Secondary Number of patients infused with planned target dose Feasibility of the manufacturing process in autoimmune disorders. Day 1
Secondary Change from pre-dose up to 2 years in the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score SLEDAI-2K scores are between 0 and 105, a higher score represents a higher disease activity. Pre-dose, up to 2 years
Secondary Change from pre-dose up to 2 years in Physician's global assessment (PGA) The Physician's Global assessment is a visual analog scale from 0 to 3, 0 represents no activity and 3 represents severe disease activity. Pre-dose, up to 2 years
Secondary Change from pre-dose up to 2 years in Lupus Low Disease Activity State (LLDAS) LLDAS is a composite measure based on: SLEDAI-2K = 4, with no activity in major organ system (renal, central nervous system, cardiopulmonary, vasculitis, and fever) and no hemolytic anemia or gastrointestinal activity, current, no new lupus disease activity compared with the previous assessment, prednisone (or its equivalent) dose = 7.5 mg/day, PGA (scale 0-3) = 1, well tolerated standard maintenance doses of immunosuppressive lupus therapy. Pre-dose, up to 2 years
Secondary Remission rate Remission as specified by Definitions Of Remission In Systemic Lupus Erythematosus (DORIS) criteria: Clinical SLEDAI=0, PGA<0.5 (0-3) irrespective of serology.
The patient may be on antimalarials, low-dose glucocorticoids (prednisolone =5 mg/day), and/or stable immunosuppressive therapy including biologics.
Up to 2 years
Secondary Change from pre-dose up to 2 years in Urinary protein creatinine ratio (UPCR) Change in the value of UPCR. Pre-dose, up to 2 years
Secondary Incidence of Complete renal response (CRR) Number of participants who achieved CRR. Up to 2 years
See also
  Status Clinical Trial Phase
Terminated NCT03843125 - A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) Phase 3
Recruiting NCT05698173 - Systemic Lupus Erythematosus and Accelerated Aging N/A
Active, not recruiting NCT01649765 - Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy Phase 2
Recruiting NCT05704153 - Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A) N/A
Completed NCT05048238 - Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus Phase 1
Recruiting NCT06056778 - The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Completed NCT04358302 - Individual Patient Exposure and Response in Pediatric Lupus N/A
Completed NCT03802578 - The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients N/A
Completed NCT02554019 - Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus Phase 2
Recruiting NCT04835883 - Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients Phase 2
Terminated NCT02665364 - Phase IIb Study of IFN-K in Systemic Lupus Erythematosus Phase 2
Completed NCT00278538 - Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus Phase 2
Completed NCT00069342 - Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Completed NCT03252587 - An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus Phase 2
Terminated NCT02066311 - Nelfinavir in Systemic Lupus Erythematosus Phase 2
Recruiting NCT01892748 - Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. N/A
Terminated NCT01689025 - An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) Phase 1
Unknown status NCT01712529 - Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients N/A
Completed NCT01475149 - Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) N/A
Completed NCT00962832 - A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus Phase 2